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1. Introduction 
This overview tries to outline some basic principles to 
identify good strategies to look for future successful 
applications of MR imaging in the clinical environ- 
ment, and define where MR may be in the year 2010. 
The author is aware of the fact that if fate will permit 
it, he will still be active in his profession and MR by 
2010, therefore jeopardizing his reputation. Neverthe- 
less, he thinks that challenging the readers and stimu- 
lating their own rebuttals to his theses will make them 
look at future opportunities more critically, and thus 
potentially define their future projects such that they 
will have a higher chance to proceed. 
Predicting the future is difficult, a commonplace 
statement, and in order to prevent the reader from 
skipping this article and go to the next contribution, the 
author obviously has to start with a disclaimer. The 
thoughts presented here are a digest of discussions with 
many friends, who have shaped this author's thoughts. 
However, the responsibility for the statements are all 
his. All omissions and inclusions, all names which are 
improperly mentioned and not mentioned are the au- 
thor's responsibilities and he is aware of the fact that 
many brilliant researchers will be unhappy with his 
statements, and some may be happy. This contribution 
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is intended to stimulate discussion and so the author 
will not try to say anything just in order not to be 
wrong or to offend, but will try to stick his head out. 
The history of Magnetic Resonance in Medicine, is 
such that there always have been heated but stimulating 
discussions, including fist fights by protagonists of 1.5 
and 0.5 T systems in the early MR days. 
This contribution will be divided into four parts; first 
an introduction, second a part where the stage is set for 
the predictions, third the discussion of the predictions 
proper and fourth the conclusions and suggested invest- 
ment strategies. While predicting the future is difficult, 
the author will be in good company when making 
mistakes: in fact, Lord Kelvin described the discovery 
of X-rays a hoax. Why is it so difficult to predict the 
future? Our sciences evolve steadily, and steady devel- 
opment is predictable by linear extrapolation. But his- 
tory in any field of knowledge shows us that there are 
moments when the old ways of thinking: the old 
paradigms no longer are adequate guidelines. 'Revolu- 
tionary' changes in paradigms occur, as Kuhn stated 
[1]. The latter make the future unpredictable because 
suddenly a completely new approach changes the prac- 
tice of some science. I might add that these paradig- 
matic changes also make life exciting. 
In such moments, new ways have to be found which 
represent complete shifts in these paradigms. Examples 
are the discovery of quantum mechanics and the special 
theory of relativity. But the introduction of X-rays is 
also a dramatic change in the paradigms of medical 
diagnosis: suddenly it became possible to diagnose chest 
disease and bone disease with a high degree of accu- 
racy. Other paradigmatic hanges in imaging are the 
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introduction of angiography, metabolic imaging with 
radionuclides and with PET, and cross-sectional imag- 
ing. The discovery of NMR certainly was also such a 
revolution. Was the introduction of MR imaging into 
clinical medicine? In many places MR only added 
incremental benefits compared to CT, so the introduc- 
tion of CT was maybe more of a revolution. Still, there 
are important aspects in MRI which can be called 
'revolutionary' such as multiplanar imaging and other 
'revolutionary' aspects of MR to be discussed. 
To exemplify one novel aspect of MR imaging, the 
multiplanar imaging capabilities of MR, Fig. 1 shows a 
somewhat historical image, namely that of the brain of 
Richard R. Ernst, Chemistry Nobel Laureate of 1991 
for his eminent contributions to NMR. There is an 
interesting note regarding this image: morphology does 
not tell you anything about the intelligence of this 
individual. 
We conclude, that while it is important o be an 
enthusiast in the field one is working in, one should 
keep one's mind open and be fair to competing tech- 
niques. Decisive revolutions may happen in a different 
field from that one is working in. 
2. The approach to the problem 
At the outset of this presentation of predicting the 
status of clinical MR imaging in the year 2010 the key 
question to be asked is thus: is there a rational ap- 
proach to predict the future of clinical MR? This 
author, in fact, believes that one can establish some 
guidelines where to look for future important develop- 
ments. This may serve as sort of a flashlight o guide us 
in the dark of choosing future projects to work on. 
Fig. 1. Sagittal Tl-weighted image (1986) of Professor Richard R. 
Ernst, Nobel Laureate in Chemistry 1991 and inventor of Fourier 
transform imaging and spectroscopy. 
What are the medical imaging needs? Where are 
major unsolved questions m diagnosis and disease man- - 
agement, with imaging playing a vital role? 
Three areas come to my mind, where progress will be 
very important for disease control: affective disorders, 
atherosclerotic cardiovascular disease and tumor imag- 
ing. Characterization of schizophrenia, dementia and 
depression has been difficult and there are guarded 
hopes that receptor imaging may eventually help to 
unravel some of the mysteries of these disease pro- 
cesses. There remain vast uncharted territories, where 
imaging may be relevant, but there is little hope that 
the sensitivity of MR will eventually reach a level where 
receptors can be imaged. This will likely remain the 
domain of nuclear imaging techniques. In the cardio- 
vascular system we are pretty good in imaging. Blind 
spots are the non-invasive imaging of atherosclerotic 
plaques, the early detection of  stroke and high resolu- 
tion ischemia imaging. While imaging of molecular 
processes using MR might also be interesting, this is 
too far away to be considered here, cardiac MR spec- 
troscopy is easily the greatest challenge in MR. Tumor 
imaging for staging purposes is still suboptimal in many 
metastatic tumors. Higher sensitivity and specificity 
imaging is very desirable and metabolic imaging is of 
great hope in this area. Tumor therapy is crude, better 
methods to monitor tumor development under therapy 
are dearly needed. 
Combining the list of where imaging is needed and 
the list of the number of measurable and changeable 
MR parameters, the future for MR looks bright indeed, 
and one could stop here and say, MR will thrive on its 
'random walk' in the dimensions comprising all the 
changeable MR parameters. There will be one billion 
more papers on MR and the annual meeting of the 
ISMRM will have replaced RSNA by 2010, since no- 
body uses any other imaging modality any more, etc. 
On the other hand, a critical appraisal of the break- 
throughs in MR which have led to substantial changes 
in clinical disease management shows a somewhat dif- 
ferent picture. 
The introduction of spin-echo and gradient-echo se- 
quences and the introduction of contrast media have 
been basic, and led to MR imaging becoming the 
premier imaging modality of the brain and the muscu- 
loskeletal system. Introduction of flow quantification 
has given us the gold standard tool for flow measure- 
ments, although the relevance of such measurements in 
clinical practice is limited. The introduction of the 
RARE pulse sequence was an important step towards 
the introduction of hybrid sequences which seem to be 
the key to rapid abdominal imaging. The introduction 
of functional magnetic resonance imaging (fMRI) and 
the use of MR to guide minimally invasive procedures 
may have an important impact, but at least fMRI so far 
has had much less of a clinical impact, than one might 
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expect from the number of papers published in this 
9 field. The clinical impact leader of the last two years is 
clearly contrast media enhanced MR angiography. 
Even in a complex technology like MR imaging, the 
relatively simple concepts have prevailed in clinical 
practice: these principles can be summarized easily: 
'high contrast-high resolution-high speed'. 
So, while MR imaging has not revolutionized cross- 
sectional imaging, it has become very important in 
brain and musculoskeletal imaging, provides ome good 
body imaging and, recently, good angiograms. On the 
other hand, there are important imaging needs not yet 
successfully covered by MR. Notable examples are: 
imaging of lung parenchyma, tumor staging, cardiac 
one-stop-shop imaging, metabolic imaging; and MR is 
still relatively costly. So, as in many fields of science, 
one notes a great discrepancy between the number of 
papers published in the field of MR and their clinical 
impact. Hence, when looking over the MR literature or 
reviewing a manuscript, in the mind of this author a 
statement keeps surfacing increasingly frequently, 
which may even become his reviewer signature: 
'So what7 
The flexibility of MR imaging is in fact at the same 
time its virtue and its danger, much more so than with 
the other imaging modalities. So many things are possi- 
ble by changing various parameters, that MR produces 
many great but also lots of irrelevant things. Care has 
to be taken that MR will not eventually find itself in a 
tower of Babylon situation (Fig. 2) where even people 
within the field do not understand each other any more. 
It is a firm belief of any scientifically trained person, 
that one should keep things as simple as possible, and 
MR can easily seduce us to get more and more com- 
plex. By looking back at the brief history of clinical 
MR imaging this appears to be true as well. An exam- 
ple for this contention is shown in Fig. 3. The MR 
researchers partly engaged in the basis of imaging have 
always been struck by the beauty of the physics MR 
angiography using time of flight and phase contrast 
methods, and look where these methods are now! Al- 
most completely blown away by a very simple and 
eminently stable high speed-high resolution technique: 
contrast media enhanced magnetic resonance angiogra- 
phy (MRA). 
'Fourier Elephant' [2], a free interpretation of An- 
toinede St. Exupery's famous drawings in the book 
'The Little Prince' which 'is a literary must for every 
individual in this world [3]. Rarely we have the quality 
of data that multiparameter fitting with more than a 
few parameter yields reliable results. 
Thus, if you engage in a project, where introduction 
into clinical practice will require multiparameter fitting 
and reliably detecting 2% changes, think twice before 
spending your energy. Things which are too complex to 
implement in a clinical environment often do not work 
well and are eventually replaced. As an example, Fig. 5 
represents data of perfusion imaging of the heart using 
MR and PET, illustrating two basic principles of perfu- 
sion imaging: bolus tracking and wash-in experiments 
[2]. Finding an MR contrast agent which sticks to tissue 
in proportion to regional perfusion may be much more 
elegant than input deconvolution fitting, which cur- 
rently has to be done to extract perfusion information 
from MR images. Nuclear medicine tracers used in 
imaging myocardial perfusion are wash-in agents, here 
ammonia rest and stress as well as glucose metabolism 
PET images. While MR perfusion imaging with input 
deconvolution may eventually consistently work, it 
would be a lot nicer to have a MR contrast medium 
which sticks for a long time in the heart like the nuclear 
medicine agents. Would such MR contrast agents be 
available, one could just use standard sequences for 
cardiac imaging to measure myocardial perfusion. 
Thus, rule number 1 is: 
'Offer the clinician simple experiments, because with fo 
ur parameters you can fit an elephant.' 
Rule number 2 is: 
'Go for big effects of the order of 100-1000%, they are 
always more reproducible and make the measurement 
stable, which is needed because the patient is usually 
unstable.' Contrast agent-enhanced MRA works so 
well because there is almost no signal other than that 
from the blood vessels, as illustrated in an example of a 
patient with aneurysmatic thigh disease (Fig. 6). Rule 
number 2 is at the same time a caveat for fMRI: it is a 
very interesting technique but signal changes are but a 
few percent. Hence, the method is technically demand- 
ing and 'the threshold of nonsense production is low'. 
This statement should not distract from the fact that 
fMRI has developed into a formidable research tool. 
3. The six rules 
This leads me to formulate some rules where to look 
for clinically useful Progress. Rule number 1 has pre- 
cisely to do with keeping things simple. With four 
parameters you can fit an elephant and with six the fit 
is perfect! This is illustrated in Fig. 4, which shows the 
Rule number 3 concerns spatial and contrast 
resolution. 
'A disease process is often 1 cm or less in size and 
should be readily detectable.' 
Critical structures uch as lymph nodes have this 
dimension, and this is indeed the technical imitation 
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Fig. 2. The Tower of Babylon; Pieter Breugel, the Eider, adorned with multiple abbreviations for pulse sequences. Allegory for potential 
communication problems within the MR community. The meaning of the abbreviations is defined for xample in Ref. [5]. 
Fig. 4. The 'Fourier Elephant', redrawn after St. Exupery, showing that with four parameters one can fit an elephant and with six of them even 
well. This is to document that overanalysis of data will probably ield the desired results but they may be meaningless9 
for clinical MR spectroscopy at this point. The small 
size of the pathology to be looked for and the inordi- 
nate amount of data in cross-sectional images makes 
morphological imaging clinically so challenging in this 
setting, particularly in tumor staging. This is il lustrated 
by a page of a Richard Scarry children's book (Fig. 7) 
[4]. The task for a child is to find :Lowly the Worm'  in 
Fig. 7a in analogy to finding a lymph node or other 
small pathological structures on a large number of CT 
or MR sections (Fig. 7b). In this circumstance it is 
useful to have an imaging method which highlights the 
pathology with excellent contrast, and blurs irrelevant 
structures, so that the lesion lights up; spatial resolution 
is not everything, the contrast has to be appropriate. 
This is il lustrated in Fig. 8(a). In MR,  classically this 
can be achieved to some degree by acquiring T2- 
weighted images, but there are many normal structures 
showing high signal intensity even on T2-weighted im- 
ages. A method providing very high contrast at rela- 
tively good resolution is PET imaging, which in 
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extended tumor staging seems to be the method of 
choice as illustrated on the right by a 3 mm melanoma 
metastasis. 
Rule number 4 concerns good data acquisition: 
'Where there is no data, there is no data.' 
By milking poor data, little additional substance can 
be produced. Postprocessing is only useful when the 
data set on which you run the postprocessing al- 
gorithms are sound. There are some very elegant filter- 
ing techniques able to cull information from temporal 
data series such as auto- and cross correlation analysis 
used in the postprocessing of fMRI  images [5], but 
there the data is hidden in a series of images not 
obvious to the observer. However, stacks of images in a 
3D data set with poor signal-to-noise ratio will not get 
better by filtering, just more pleasing to look at. The 
very high signal-to-noise ratio is the reason why con- 
trast media enhanced MRA is so good; there is lots of 
good data in an MR angiographic image. 
Rule number 5 relates to contrast media enhance- 
ment in MR: 
'MR contrast agents act at concentrations of 10 .4 .  
10 -s  tool, receptor interactions occur typically at 
10 -9_10-  12 mol.' 
The consequence of this observation is, that MR 
contrast agents cannot be expected to produce enhance- 
(A) 
@ 
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9 
I 
:ii 
ment in all desirable settings. Specifically, processes 
which occur in the nano- to picomolar range, for 
example dopamine receptor interactions as shown in a 
PET scan (Fig. 9) cannot be visualized by MR imaging. 
MR signal changes occur only when contrast-active 
substances are present in the micromolar ange, such as 
is the case with blood pool markers. 
Rule number 6 is simple and an old wisdom with all 
imaging specialists who have been around for a while: 
'Faster is better.' 
Whenever high resolution images can be acquired 
faster than slower, the methodology is bound to prevail 
because motion artifacts disappear. This is again well 
exemplified with contrast media enhanced MRA, where 
next to the good contrast the fact that data can be 
acquired in a breath hold, has made this technique to 
become so successful. 
4. Predictions 
Using these rules we can now start predicting where 
MR may be in the year 2010. The six rules provide a 
base. Before trying to make some predictions, it has to 
be reiterated that we cannot predict 'revolutionary' 
changes in imaging because some new technological 
(B) 
Fig. 3. Time-of-fli~.ht MRA (A) and contrast agent-enhanced MRA (B) demonstrating the superior quality of modem contrast agent-enhanced 
MRA. 
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be used only for regional tumor staging and have little 
impact on imaging of metabolism and for tissue specifi- 
cation. Quantitative MR imaging beyond flow will be 
difficult mainly because of the difficulty to quantify 
MR signals in general. 
Finally, what was stated emphatically at the begin- 
ning, will have to be reiterated at the end of this 
treatise. All the conjectures made here may be wrong 
because any number of unpredictable 'revolutionary' 
inventions of any of the readers of this text, or possibly 
(a) 
(b) 
Fig. 13. Patient with a pancreatic carcinoma showing (a) l cal disease on MR imaging and (b) extended disease on a corresponding coronal whole 
body PET scan section. 
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Fig, 5. MR perfusion imaging (a) and PET perfusion imaNng (b). The former shows relatively good spatial resolution on this two-shot echo planar 
image pre- (left) and approximately 30 s after injectio n of contrast media (right), while the latter shows rest and stress ammonia PET images with 
good contrast and a potential for relatively simple quantification. The bottom row depicts pixelwise perfusion reserve. 
development may suddenly make much work obsolete, 
as has occurred with contrast-agent enhanced MRA 
doing away with much of the other MR angiographic 
techniques. 
Brain imaging in the year 2010 will no longer make 
use of CT in most cases. Morphology, early stroke 
detection and even emergency trauma cases will be 
done in MR. fMRI will be a useful adjunct mostly 
during brain surgery, but will have no substantial im- 
pact on understanding affective disorders such as de- 
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pression. This is because affective disorders and 
schizophrenia re more likely related to neuroreceptor 
derangements, fMRI will thus remain an interesting 
research tool, but plateau earlier in its clinical applica- 
tions than many of us expect because of the limitations 
of the method and the complexity of the brain. 
Morphological and functional brain data will be 
fused on a regular basis and integrated systems 
combining modalities like CT and PET may emerge, 
and real-time fusion of interventional MR and CT with 
PET data during brain surgery may become standard. 
Complex tumor surgery will occur to a large extent in 
open MR units, as identification of tumor margins is 
considered to be of major importance for successful 
disease control. Smaller dedicated head units will make 
brain MR imaging more cost effective. 
In cardiovascular imaging, contrast enhanced MRA 
will have replaced much of vascular angiography by 
2010, a process which has started already now in all 
institutions with high end MR scanners. 
With the advent of blood pool contrast agents, opti- 
mization of data acquisition will be accomplished so 
that MRA can consistently visualize the coronaries and 
diagnose stenoses in such a large fraction of patients, 
that MRCA will show clinical utility. Since visualizing 
the coronaries is the major driving force to make MR 
imaging of the heart relevant and cost effective, the 
other cardiac MR techniques, i.e. cardiac anatomic 
imaging, wall motion imaging, MR imaging of cardiac 
volumetry and even perfusion imaging which may re- 
main complex, will be used together with MRCA to 
make cardiac MR the long asked for 'one-stop-shop' 
heart examination, which cardiac MR specialists have 
been talking about for the last decade. 
Fig. 6. Contrast enhanced MRA of a patient with aneurysmatie 
disease of the arteries of the lower extremities. 
It is doubtful for toxicity reasons but not impossible, 
that a wash-in agent, i. e. an agent sticking to the 
myocardium in proportion to regional perfnsion, will
become available as MR perfusion agent. If such an 
agent would indeed be available, perfusion imaging as 
currently used in nuclear medicine can be done with 
MRI which would make MR perfusion imaging in itself 
a method very competitive with thallium and Tc-MIBI/ 
tetrofosmin imaging due to the much better spatial 
resolution obtained with MR imaging. 
More complicated methods like myocardial tagging 
will unlikely enter clinical routine as no impact on 
management of disease has been derived from this 
methodology at this point, although tagging may re- 
main an important research tool. Metabolic imaging of 
the heart with MR spectroscopy will not enter clinical 
routine because of the lack of spatial-temporal resolu- 
tion. On the other hand, it is reasonable to assume, that 
many cardiovascular interventions will be done under 
MR guidance in the year 2010, not only because of the 
lack of ionizing radiation to the physician, but because 
of the added value of 3D imaging, plaque characteriza- 
tion and flow measurements to control results. Fig. 10 
depicts key frames in a percutaneous transluminal an- 
gioplasty (PTA) performed under MR guidance. Fig. 
11 depicts a MR 'road map' with two instrument tips 
superimposed in real time over it. Fig. 12 is an example 
of intravascular imaging with anatomic orrelation us- 
ing a balloon catheter fitted with a local coil. As 
understanding plaque composition is important, in- 
travascular MR imaging during an intervention will 
become routine and the tools to support intravascular 
imaging and intravascular interventions are being de- 
veloped. It has to be noted that endovascular MR 
imaging is highly competitive to endovascular ultra- 
sound because the cost of the probes is going to be 
much lower. 
In the gastrointestinal and genitourinary systems MR 
will take over most CT indications by 2010 and become 
the major morphological staging method in the abdo- 
men and pelvis. This is a result of the better inherent 
contrast, the contrast material, and the hybrid pulse 
sequences now affording breath-hold high-quality im- 
ages of the abdomen. 
In the musculoskeletal system MR will cement its 
role as prime morphological imaging modality in the 
next decade. In the extremities, cheap units will become 
widespread and MR will be used as screening modality 
for back pain. Functional examinations will become 
relevant as more open MR units become available. 
Furthermore, MR guided surgery will become com- 
monplace in musculoskeletal imaging. Thermoablation 
of tumors such as lumbar disk disease, soft tissue 
tumors, etc. will be done under MR control. 
General predictions are the following: short-bore 
high-field MR scanners will become available not only 
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(a) 
Co) 
Fig. 7. (a) A page from a Richard Scarry children's book depicting 'Lowly the Worm' sitting in an apple mobile (arrow); (b) CT scan showing 
a small possibly pathological structure in the subcutaneous ti sue of the right posterior thoracic region, which was prospectively overlooked in a 
stack of 40 sections (arrow). 
for imaging but for interventions, mainly vascular inter- 
ventions uch as stenting, which will be routinely done 
under MR guidance in view of excellent vascular con- 
trast, but also contrast against the surrounding soft 
tissues in all vessels except he coronaries where spatial 
resolution may still be a limiting factor for guiding 
interventions, but not for depiction of anatomy. There 
will be widespread use of open MR systems for mini- 
mally invasive surgery, and miniaturization technolo- 
gies will bring forth MR compatible mini-devices useful 
in measuring MR signals anywhere from within the 
body which can even be left in place for future MR 
measurements. 
The author does not foresee a substantial increase in 
the role of metabolic MR imaging, and the pharmacol- 
ogy and physiology of producing MR contrast media 
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which can label physiological processes beyond vascular 
and RES enhancement may be so prohibitively difficult, 
that not too many agents will be available with such 
properties by 2010. while MR will be the primary 
morphological tumor staging modality to evaluate local 
disease spread, PET will be the method of choice for 
whole body staging to screen whether the tumor has 
spread to distant sites (Fig. 13). 
Investment strategies concerning high technology 
medical imaging equipment herefore should be as fol- 
lows. University hospitals and large clinical centers will 
have to further invest heavily into MR and the number 
of MR units will have surpassed that of  CT scanners 
and outnumber them by at least 2:1. While standard 
magnets will still be in use, more dedicated units will 
have to be purchased: head units, extremity units, open 
(a) 
(b; 
Fig. 8. (a) Same page from the children's book shown in Fig. 7(a), but now allstructures except that containing 'Lowly the Worm' are blu red; 
thus, much more contrast is vailable. In tumor imaging, this is exemplified by a PET scan demonstrating a 3 mm melanoma metastasis. 
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Fig. 9 
Fig. 10 
Fig. 9. PET scan using a dopamin receptor marker (F-18-DOPA) showing the caudate and striatum only. 
Fig. 10. PTA (percutaneous transluminal angioplasty) of an iliac stenosis pre, during and after balloon anNoplasty, monitored with a 0.5 T 
interventional open mag-net (note that this MR imager configuration and field strength are not optimal for this purpose and short bore, high field 
magnets will be used. 
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Pig. 11 
Fig. 12 
Fig. I i. Road map produced with contrast media enhanced MRA with the superposition of two instrument positions (Courtesy of Dr M. Ladd). 
Fig. 12. Intravascular imaging with a local coil fitted onto a balloon catheter which is inflated during imaging. 
systems for performing surgery and short bore systems 
as general units or units providing also for interven- 
tionat procedures. Investment into 4 T and beyond will 
still be mainly for research rather than clinical 
purposes. 
University centers will also have to install PET cen- 
ters as PET will become the major tumor staging 
modality for extended disease. For smaller centers, 
specialized MR units will still be necessary because th y 
are cost effective when the volume is large enough. 
Expensive open units for surgery and high field units 
will probably not spread to such sites. 
In conclusion, I predict hat MR imaging will be the 
most important diagnostic imaging modality in 2010. 
Many interventions will be guided by MR using new 
virtual reality possibilities and microelectronic con- 
cepts. Furthermore, MRI wiU be substantially cheaper 
than today due to the large scale introduction of dedi- 
cated smaller units. Even MRI has technical limitations 
and may stay inferior in some imaging areas. MR will 
remain inferior in imaging the lung parenchyma nd 
compact bony structures, where CT will prevail. It will 
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of somebody not working in the field of MR, may 
change the outlook in the clinical environment of MR 
to such an extent, that all the premises on which the 
predictions made here are based, have become obsolete. 
Yhus, it is important hat we remain open to ideas of 
others and to ideas surfacing in other neighboring fields 
of knowledge, even looking occasionally beyond the 
imaging horizon, as for example at the economic envi- 
ronment which will probably very heavily affect our 
clinical work in the next 10 years. 
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